Hepion Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 22
- Market Cap
- $4.5M
- Website
- http://www.hepionpharma.com
- Introduction
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
Clinical Trials
8
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects
- Conditions
- NASH With Fibrosis
- Interventions
- Drug: [14C]-rencofilstat 225mg
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Hepion Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05737433
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3
- Conditions
- NASH With Fibrosis
- Interventions
- Drug: rencofilstat, 75 mgDrug: rencofilstat, 150mgDrug: rencofilstat, 225 mg
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Hepion Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05461105
- Locations
- 🇺🇸
Arizona Liver Health-Chandler, Chandler, Arizona, United States
🇺🇸Arizona Liver Health-Glendale, Peoria, Arizona, United States
🇺🇸Adobe Clinical Research, LLC, Tucson, Arizona, United States
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
- Conditions
- Nonalcoholic Steatohepatitis (NASH)NAFLDFibrosis, Liver
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Hepion Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05402371
- Locations
- 🇺🇸
Medical Affiliated Research Center, Huntsville, Alabama, United States
🇺🇸Arizona Liver Health-Chandler, Chandler, Arizona, United States
🇺🇸Arizona Liver Health, Peoria, Arizona, United States
A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects
- Conditions
- Fibrosis, LiverNAFLD - Nonalcoholic Fatty Liver DiseaseNASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: Placebo (3 softgels)Drug: CRV431 75mgDrug: Placebo (1 softgel)Drug: CRV431 225mg
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Hepion Pharmaceuticals, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT04480710
- Locations
- 🇺🇸
Conquest Clinical Research, Orange, California, United States
🇺🇸Alliance Clinical Research, Poway, California, United States
🇺🇸La Salud Research, Inc., Miami, Florida, United States
A Study in Healthy Volunteers
- Conditions
- Liver DiseasesHepatitis BInfectious Disease
- Interventions
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- Hepion Pharmaceuticals, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT03596697
- Locations
- 🇺🇸
Celerion, Inc, Lincoln, Nebraska, United States
🇺🇸Pinnacle Clinical Research, San Antonio, Texas, United States